![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 9
Zeitschriftenartikel
Stahler, A.; Heinemann, V.; Clemens, G.; Crispin, A.; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling-Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; Einem, J. C. von; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A. und Modest, D. P.
(2016):
Prevalence and influence on outcome of Neuregulin- (NRG1), HER2/neu- and HER3-expression in patients with metastatic colorectal cancer (mCRC) treated with irinotecan-based first-line regimens (FUFIRI vs. mIROX) in the FIRE 1-trial.
In: Oncology Research and Treatment, Bd. 39: S. 72
Stahler, A.; Heinemann, V.; Giessen-Jung, C.; Crispin, Alexander; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling-Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; Einem, J. C. von; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A. und Modest, D. P.
(2015):
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
In: International Journal of Cancer, Bd. 138, Nr. 3: S. 739-746
Giessen, C.; Fischer von Weikersthal, L.; Laubender, Rüdiger P.; Stintzing, S.; Modest, D. P.; Schalhorn, A.; Schulz, C. und Heinemann, V.
(2013):
Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial.
In: British Journal of Cancer BJC, Bd. 109, Nr. 6: S. 1428-1436
Giessen, C.; Laubender, Rüdiger P.; Fischer von Weikersthal, L.; Schalhorn, A.; Modest, D. P.; Stintzing, S.; Haas, M.; Mansmann, Ulrich und Heinemann, V.
(2013):
Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan-based randomized first-line trial.
In: Cancer Science, Bd. 104, Nr. 6: S. 718-724
Giessen, C.; Stintzing, S.; Laubender, Rüdiger P.; Ankerst, Donna Pauler; Schulz, C.; Moosmann, N.; Modest, D. P.; Schalhorn, A.; Fischer von Weikersthal, L. und Heinemann, V.
(2011):
Analysis for Prognostic Factors of 60-day Mortality: Evaluation of an Irinotecan-Based Phase III Trial Performed in the First-Line Treatment of Metastatic Colorectal Cancer.
In: Clinical Colorectal Cancer, Bd. 10, Nr. 4: S. 317-324
Wilkowski, R.; Pachmann, S.; Schymura, B.; Dellian, M.; Schalhorn, A. und Dühmke, Eckhart
(2005):
A new concurrent chemotherapy with vinorelbine and mitomycin C in combination with radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.
In: Onkologie, Nr. 10: S. 491-495
[PDF, 90kB]
Stemmler, J.; Stieber, P.; Szymala, A. M.; Schalhorn, A.; Schermuly, M. M.; Wilkowski, R.; Helmberger, T.; Lamerz, Rolf; Stoffregen, C.; Niebler, K.; Garbrecht, M. und Heinemann, Volker
(2003):
Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?
In: Onkologie, Nr. 5: S. 462-467
[PDF, 115kB]
Stemmler, Joachim; Heinemann, Volker und Schalhorn, A.
(2002):
Capecitabine as second-line treatment for metastatic cholangiocarcinoma: A report of two cases.
In: Onkologie, Nr. 2: S. 182-184
[PDF, 49kB]
Stemmler, J.; Weise, A.; Hacker, U.; Heinemann, Volker und Schalhorn, A.
(2002):
Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure.
In: Onkologie, Nr. 1: S. 60-63
[PDF, 59kB]